Aptorum Group Ltd Class A (APM)

Currency in USD
0.832
-0.038(-4.37%)
Closed·
0.854+0.022(+2.64%)
·
APM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8200.871
52 wk Range
0.6504.470
Key Statistics
Prev. Close
0.87
Open
0.867
Day's Range
0.82-0.871
52 wk Range
0.65-4.47
Volume
83.56K
Average Vol. (3m)
153.57K
1-Year Change
-15.9495%
Book Value / Share
2.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Aptorum Group Ltd Class A Earnings Call Summary for Q4/2024

  • Record Q4 2024 revenue of $254M, net income of $19.2M ($0.12/share), and adjusted EBITDA of $62.9M
  • Stock declined 3.13% in last session; 90% drop over past year but 2.75% gain in past week
  • 2025 gold equivalent production guidance: 102,900-117,200 ounces; CapEx forecast: $28.2M-$32M
  • Successful integration of Golden Queen, doubling company size in revenue and production
  • Focus on operational efficiencies, exploration, and inorganic growth opportunities for 2025
Last Updated: 03/19/2025, 10:03 AM
Read Full Transcript

Earnings

Latest Release
Mar 27, 2026
EPS / Forecast
-0.04 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

APM Income Statement

Compare APM to Peers and Sector

Metrics to compare
APM
Peers
Sector
Relationship
P/E Ratio
−5.0x−4.5x−0.4x
PEG Ratio
−0.070.120.00
Price / Book
0.3x3.7x2.6x
Price / LTM Sales
-4.4x3.0x
Upside (Analyst Target)
-122.0%55.8%
Fair Value Upside
Unlock2.4%8.3%Unlock

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
923.99K11.35%768.86K
Public Companies & Retail Investors
7.22M88.65%6.01M
Total
8.14M100.00%6.78M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
L1 Global Manager Pty Ltd4.71%383,750319
L1 Capital Global Opportunities Master Fund, Ltd.4.71%383,750319

People Also Watch

1.1800
DOGZ
+4.42%
6.2900
KPLT
-0.47%
0.760
DTSS
-1.94%
1.9000
BTOG
0.00%
3.39
RPAY
+2.11%

FAQ

What Is the Aptorum A (APM) Stock Price Today?

The Aptorum A stock price today is 0.832 USD.

What Stock Exchange Does Aptorum A Trade On?

Aptorum A is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Aptorum A?

The stock symbol for Aptorum A is "APM."

What Is the Aptorum A Market Cap?

As of today, Aptorum A market cap is 6.780M USD.

What Is Aptorum A's Earnings Per Share (TTM)?

The Aptorum A EPS (TTM) is -0.185.

From a Technical Analysis Perspective, Is APM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Aptorum A Stock Split?

Aptorum A has split 1 times.

How Many Employees Does Aptorum A Have?

Aptorum A has 1 employees.

What is the current trading status of Aptorum A (APM)?

As of Jun 21, 2026, Aptorum A (APM) is trading at a price of 0.832 USD, with a previous close of 0.870 USD. The stock has fluctuated within a day range of 0.820 USD to 0.871 USD, while its 52-week range spans from 0.650 USD to 4.470 USD.

What Is the APM Premarket Price?

APM's last pre-market stock price is 0.854 USD. The pre-market share volume is 83,560.000, and the stock has decreased by 0.022, or 2.640%.

What Is the APM After Hours Price?

APM's last after hours stock price is 0.858 USD, the stock has decreased by 0.026, or 3.090%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.